U.S. Paper and Forestry Products Stock News

Columbia Sportswear recently reported fourth-quarter and full-year 2025 results that exceeded its own guidance, issued 2026 earnings and sales forecasts calling for modest growth, and affirmed a regular quarterly dividend of US$0.30 per share payable on March 20, 2026. The company highlighted that stronger-than-expected U.S. demand, broad-based international growth, and its ACCELERATE Growth initiatives helped offset weather and tariff pressures while supporting a cautiously constructive...

Doximity recently came under pressure as part of a broader sell-off in technology and healthcare software stocks, driven by investor worries about potential disruption from artificial intelligence. Despite this pressure, analyst expectations still point to higher quarterly revenue and growth in larger customers, even as projected earnings per share soften slightly compared to a year earlier. Given the recent 10.5% seven-day share price decline, we'll examine how AI-disruption concerns shape...

If you are wondering whether Moderna's current share price reflects its true worth, you are not alone. This article will walk through what the numbers are saying about value. Moderna's stock recently closed at US$42.20, with a 30 day return of 36.7%, a 7 day return reflecting a 7.2% decline, and a 3 year return showing a 75.3% decline. This contrasts with a 23.5% gain over the last year and a 36.7% return year to date. Recent coverage has focused on how investors are reassessing vaccine...

In the past few days, The Cooper Companies amended its 2021 term loan agreement, extending US$950 million of term loans to February 3, 2031, while lifting the cap on incremental borrowing and adding optional rating-based pricing. At the same time, Diamond Hill Capital’s Large Cap Fund disclosed a new position in the company, underscoring institutional interest in its contact lens and women’s health and fertility businesses despite current headwinds. Next, we’ll examine how the extended debt...

AXT (AXTI) is back on many watchlists after investor interest climbed alongside AI driven bandwidth demand, as the company’s Indium Phosphide substrate wafers sit at the heart of data center and optical communications build outs. See our latest analysis for AXT. AXT’s share price has been highly volatile, with a 14.8% 7 day share price return and a 116.9% 90 day share price return. The 1 year total shareholder return is extremely large, pointing to strong momentum despite the recent 5.7% 1...

Why Atmos Energy (ATO) is on investors’ radar after its latest results Atmos Energy (ATO) recently reported first quarter earnings, with sales and net income figures above the prior year period. The company also affirmed full year earnings guidance and continued its long running quarterly dividend. See our latest analysis for Atmos Energy. Despite a relatively muted 90 day share price return of a 2.19% decline to US$168.81, Atmos Energy’s 1 year and 5 year total shareholder returns of 21.22%...

If you are wondering whether Kyivstar Group's current share price reflects its true worth, you are not alone. This article focuses squarely on that question. The stock recently closed at US$11.83, with a 7 day return of 6.0% decline, a 30 day return of 10.9% decline, and a 1 year return of 14.4%, which points to shifting expectations and risk perceptions over different time frames. Recent news coverage around Kyivstar Group has focused on its position as a US listed telecom player with...

Advanced Micro Devices (NasdaqGS:AMD) reported Q4 2025 results that exceeded prior expectations, driven by AI focused data center products. The company issued cautious Q1 2026 guidance, raising questions about how quickly AI related demand will translate into near term growth. AMD expanded its partnership with GIGABYTE to bring its AI technology more deeply into consumer and creator devices, extending beyond data centers. With a current share price of $242.11, Advanced Micro Devices has...

Samsara (NYSE:IOT) is expanding its Canadian footprint with local data hosting, domestic logistics partnerships, and new AI safety features. The rollout focuses on data residency, regional hardware fulfillment, and support for customers operating in remote parts of Canada. The company is tailoring its connected operations platform to Canadian fleets and industrial operators that face strict compliance and connectivity requirements. Samsara runs a connected operations platform that links...

If you are wondering whether Trane Technologies at around US$435 a share still offers reasonable value, you are not alone. This article is aimed at helping you frame that question clearly. The stock has posted returns of 11.0% over the last 7 days, 9.4% over the past month and year to date, and 23.6% over the past year, with a very large 3 year gain and a 219.1% return over 5 years that may be influencing how the market is thinking about future expectations and risk. Recent coverage has...

Snowflake (NYSE:SNOW) has entered a multi year, $200 million partnership with OpenAI to embed advanced AI models directly into its data platform. The company is launching Cortex Code, an AI coding agent built around customer data, alongside new tools aimed at enterprise AI development and governance. These updates are designed to let enterprises build custom AI agents on their own data while keeping control, security and compliance within Snowflake’s environment. Snowflake is pushing deeper...

From what we can see, insiders were net buyers in Lindblad Expeditions Holdings, Inc.'s ( NASDAQ:LIND ) during the past...

In early February 2026, Prudential Financial reported fourth-quarter 2025 results that met revenue expectations but missed adjusted EPS forecasts, while also raising its quarterly dividend to US$1.40 per share and confronting misconduct at its Japan unit that prompted a 90-day halt in new sales and a leadership change. The combination of higher full-year net income of US$3.58 billion, an 18th consecutive annual dividend increase, and a temporary sales suspension in Japan has sharpened...

If you are wondering whether Skyward Specialty Insurance Group's current share price reflects its underlying value, you are not alone. This article is going to focus squarely on that question. The stock last closed at US$44.25, with a 1.6% decline over 7 days, a 9.0% decline over 30 days, a 9.0% decline year to date and a 5.3% decline over 1 year, set against a very large 3 year return of 124.6%. Recent news coverage has highlighted Skyward Specialty Insurance Group in the context of broader...

If you are wondering whether AbbVie at around US$225.66 is still a fair deal or starting to look stretched, this article is designed to help you put that price in context. The stock’s recent returns are mixed, with a 0.8% gain over the last 7 days, a 1.6% decline over the past month, a 1.6% decline year to date, and a 22.8% return over the past year, alongside 73.3% and 159.2% returns over 3 and 5 years. Recent headlines around AbbVie have focused on its role as a large US pharmaceuticals...

In early February 2026, Jacobs Solutions reported first-quarter sales of US$3,293.28 million and a return to net profitability, while the Gulf Coast Protection District selected the company to lead engineering design for The Gate, a major coastal storm surge barrier at Bolivar Roads in Texas. This combination of improved earnings and a flagship role in the Coastal Texas Project reinforces Jacobs’ positioning in large-scale climate resilience and critical infrastructure work, spanning...

If you are wondering whether Workiva at around US$72 per share offers fair value or a possible opportunity, you are not alone. That is exactly what this analysis will unpack. The stock has recently pulled back, with a 7 day return of an 11.1% decline, a 30 day return of a 13.2% decline, and a 1 year return of a 28.4% decline, which has also contributed to a 23.0% decline over 3 years and a 32.3% decline over 5 years. These moves have put Workiva on the radar for investors who track companies...

In January 2026, First Bancorp reported strong fourth-quarter and full-year 2025 earnings growth, increased its quarterly cash dividend to US$0.24 per share, and recorded modest net loan charge-offs alongside reserve adjustments tied to loan growth and Hurricane Helene exposure. The retirement of long-serving director and former board chair Mary Clara Capel marks a governance transition at the same time the company is reporting materially higher profitability. We’ll now examine how the...

Sangamo Therapeutics recently reported detailed Phase 1/2 STAAR study results for its Fabry disease gene therapy, isaralgagene civaparvovec, and confirmed a rolling Biologics License Application submission to the FDA under the Accelerated Approval pathway, supported by kidney function as an intermediate clinical endpoint. The company paired these clinically promising data and regulatory progress with a roughly US$24.82 million follow-on equity raise and a finance leadership change,...

In late January 2026, Microsoft reported fiscal Q2 results with revenue of US$81.27 billion and net income of US$38.46 billion, alongside record cloud revenue and the launch of its Maia 200 AI inference chip. Investors, however, fixated on moderating Azure growth, a very large US$37.50 billion AI‑driven capital spending bill, and heavy exposure to OpenAI within a US$625 billion cloud backlog, sparking concern about how quickly these AI bets will translate into durable returns. Next, we’ll...

Ardelyx (ARDX) has drawn fresh attention after securing a new US patent that extends protection for its tenapanor formulations, IBSRELA and XPHOZAH, to 2042, while also advancing IBSRELA into a Phase 3 trial in chronic idiopathic constipation. See our latest analysis for Ardelyx. Ardelyx’s recent patent win and progress with the ACCEL Phase 3 trial come after a strong run, with a 30-day share price return of 25.85% and a 1-year total shareholder return of 40.22%, alongside a small pullback...

If you are looking at Globus Medical and wondering whether the current share price lines up with its underlying worth, this article is built to walk you through that question step by step. The stock recently closed at US$87.45, with returns of 4.9% decline over 7 days, 0.2% over 30 days, 0.2% year to date, 5.1% decline over 1 year, 12.3% over 3 years, and 34.9% over 5 years, which may shape how investors think about both its potential and its risks. Recent news coverage around Globus Medical...

Labcorp Holdings (NYSE:LH) has amended its receivables purchase agreement, extending the facility’s termination date. The amendment adds an accordion feature that can increase borrowing capacity under certain conditions. The revised structure is intended to provide greater liquidity flexibility for the company’s operations and planning. Labcorp is a large diagnostics and laboratory services provider, so reliable access to funding is important for supporting day to day testing volumes and...

IDEX Corporation reported its latest quarterly results on Wednesday, with analysts having expected modest year-on-year revenue growth following a prior quarter in which the company exceeded revenue and operating income estimates. Investors are also watching IDEX’s long record of paying and raising dividends, supported by profitability and financial stability that underpin its capital-return approach. Next, we’ll examine how anticipation around the earnings release and IDEX’s dividend track...